Evidence-based Medicine and HMOs: Where are we now? Where are we going?
A number of benefits of breastfeeding, particularly protection against child infections, may be, at least partially, related to the presence of human milk oligosaccharides (HMOs). Progress in biotechnology nowadays allows the production of at least some HMOs. Two HMOs, 2-fucosyllactose (2’-FL) and lacto-N-neo-tetraose (LNnT), have recently been added to infant formula, either alone or in combination. Professor Hania Szajewska presents the results of the clinical studies done with HMO-supplemented formulas to healthy infants, which shows some favorable clinical effects and no safety concerns with regard to growth and adverse effects.
This is a video teaser with key points of the presentation of Professor Hania Szajewska during the NNI Satellite Symposia at Nutrition and Growth 2019 .
Click in the link below if you want to see Professor Hania Szajewska’s full talk:
If you liked this post you may also like